Oxaprozin


Generic Medicine Info
Contraindications
Hypersensitivity. History of bronchospasm, asthma, urticaria, or other allergic-type reactions w/ NSAIDs; active GI bleeding, severe heart failure, recent MI. CABG surgery.
Special Precautions
Patient w/ history of peptic ulcer disease and/or GI bleeding, coagulopathy, HTN, oedema, known or risk factors for CV disease, on dialysis, DM, other forms of asthma. Smokers. Severe renal and hepatic impairment. Childn. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, dizziness and blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor BP, CBC, K levels, renal function, and LFT. Monitor signs and symptoms of GI bleeding.
Adverse Reactions
Significant: Drowsiness, dizziness, blurred vision, HTN, fluid retention, oedema, decreased platelet adhesion and aggregation, prolonged bleeding time, anaemia, increased risk of hyperkalaemia, photosensitivity reactions, renal papillary necrosis (long term use). Rarely, blood dyscrasias (e.g. agranulocytosis, thrombocytopenia, aplastic anaemia). Nervous: Headache, CNS inhibition (e.g. depression, sedation, confusion), sleep disturbance, sedation. GI: Abdominal pain/distress, anorexia, constipation, diarrhoea, dyspepsia, flatulence, heartburn, nausea, vomiting. Hepatic: Increased ALT/AST. Genitourinary: Abnormal renal function, dysuria, urinary frequency. Otic: Tinnitus. Dermatologic: Pruritus, rash.
Potentially Fatal: Increased risk of CV thrombotic events (e.g. MI, heart failure, stroke); GI adverse events (e.g. inflammation, bleeding, ulceration and perforation of the stomach or intestines); anaphylactoid reactions (e.g. severe bronchospasm); serious skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis). Rarely, hepatic injury (e.g. fulminant hepatitis, hepatic necrosis, hepatic failure).
C Avoid during 3rd trimester or near delivery.
Drug Interactions
Increased risk of renal toxicity w/ diuretics, ACE inhibitors, angiotensin II receptor blockers (ARBs). Increased risk of bleeding w/ anticoagulants, antiplatelets, SSRIs, serotonin norepinephrine reuptake inhibitors. Increased risk of hyperkalaemia w/ ACE inhibitors. May increase serum conc of lithium. May increase serum concentration and prolong the half-life of digoxin. May increase the risk of methotrexate and ciclosporin toxicity. Increased risk of myelosuppression, renal and GI toxicity w/ pemetrexed. May decrease antihypertensive effect of diuretics, ACE inhibitors, ARBs, β-blockers. May decrease natriuretic effect of furosemide.
CIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AE12 - oxaprozin ; Belongs to the class of propionic acid derivatives of non-steroidal antiinflammatory and antirheumatic products.
Disclaimer: This information is independently developed by CIMS based on oxaprozin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in